Leading the Way for Biomarker Sample Analysis for Proinflammatory Cytokines in Mice Using MSD® V-PLEX Immunoassays
MPI Research has successfully completed validation of the newest multiplex option from Meso Scale Discovery® (MSD) for proinflammatory cytokines in mouse samples, the V-PLEX™ Proinflammatory Panel 1 (mouse). As the first contract research organization (CRO) to validate this multiplexed assay, MPI Research is setting the pace for providing knowledge and expertise needed by its Sponsors as they develop new drug candidates.
Applications for Biomarkers of Proinflammatory Cytokines in Mice
The MSD mouse V-PLEX is a multiplexed sandwich immunoassay that combines up to eight analytes into a single test. The biomarker analytes, IFN-., IL-1ß, IL-2, IL-4, IL-5, IL-6, KC/GRO, IL-10, IL-12p70, and TNF-a, can be used to help interpret data in a variety of drug safety studies including oncology, immunotoxicology, vaccine research, diabetes, immunomodulatory applications, biosimilars, autoimmune disease research, and inflammation. MPI Research offers its Sponsors the capabilities to conduct GLP animal studies, in addition to non-GLP cytokine sample analysis.
Roger Hayes, PhD, Vice President and General Manager of Laboratory Sciences at MPI Research, shared, “We are excited to expand our biomarker assay capabilities to aide our Sponsors as they seek to develop treatments for debilitating diseases. This effort supports our ongoing mission to provide best-in-class, early stage drug development services to bring safer, more efficacious products to market. We are confident that our Sponsors will benefit from our continued biomarker expansion, led by experts in this field: Mr. Mark Cameron, Senior Manager, Biomarkers and Immunoassay Development, and Dr. Yi Qun Xiao, Director, Immunochemistry.”
Earlier this year, MPI Research announced its completion of specialized training from MSD to run Aß42 and Total Tau immunoassays on the MSD Imager platform. The Total Tau and Aß42, biomarkers for Alzheimer’s disease, can be used to measure biomarker levels in cerebral spinal fluid from patient clinical trials.
About MPI Research
MPI Research, with global headquarters in Mattawan, Michigan, provides safety evaluation, discovery, bioanalytical, and analytical services, and early clinical services and solutions to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com
About Meso Scale Discovery
Meso Scale Discovery, a division of MESO SCALE DIAGNOSTICS, LLC, develops and markets solutions for multiplex biological assays, including assays for biomarkers, cytokines, and phosphoproteins. MSD’s platform is based on MULTI-ARRAY® technology, a proprietary combination of patterned arrays and electrochemiluminescence detection, providing multiple simultaneous measurements with exceptional sensitivity, wide dynamic range, and fast, convenient processing. For more information about MSD, visit www.mesoscale.com.